Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP („Fibrocor“), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-establish-strategic-partnership-to-launch-fibrocor-therapeutics-5430